… However, in preclinical models and early phase non-comparative studies pharmacodynamic
separation of chemotherapy and TKIs did show a synergistic effect. Methods: A randomized …

… Erlotinib is a well known FDA approved drug from category of tyrosine kinase inhibitors;
used for the treatment of lung cancer. However its use is limited because of its poor water …

… of this study was to examine the costs, outcomes, and cost-effectiveness of erlotinib compared
… nonsignificantly different between the two groups under study but also the overall cost of …

… In the current study, erlotinib had the greatest probability to rank the first among all the four
TKIs regarding ORR and 1-year PFS while afatinib rank best in 1-year and 2-year OS. Icotinib …

… This study had several limitations with the major weakness being that it was a single-arm,
non-comparative study. Unfortunately, the small numbers of patients and the diversity of these …

… to metabolize gefitinib and erlotinib has not been done. The purpose of this study was to
examine the kinetics of metabolism of gefitinib and erlotinib by individual CYP enzymes, with …

… In this study, the combination of erlotinib and sorafenib in patients with recurrent GBM
was intended to inhibit the EGFR and Ras signal transduction pathways, both of which are …

… Study subjects and data collection This study included 599 patients with EGFR-mutant
NSCLC who started first-line gefitinib, erlotinib, afatinib treatment for advanced NSCLC at …

… The results of this study indicate that although increasing doses of erlotinib correlate
positively with inhibition of receptor activation and downstream signaling, these effects are not …

… erlotinib and afatinib in SCC of the lung. The authors explore the rationale of targeting EGFR
in SCC and the pharmacological properties of erlotinib … 8 trial, which compared erlotinib and …